About Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc. is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company's lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects. In addition to bempedoic acid as monotherapy, the Company is also developing bempedoic acid in a fixed dose combination with ezetimibe, an approved, non-statin, oral, LDL-C lowering therapy. As of December 31, 2016, the Company was engaged in conducting its global Phase III clinical development program for bempedoic acid.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ESPR
- CUSIP: N/A
- Web: www.esperion.com
Capitalization:- Market Cap: $1.09 billion
- Outstanding Shares: 25,693,000
Average Prices:- 50 Day Moving Avg: $51.52
- 200 Day Moving Avg: $43.30
- 52 Week Range: $9.40 - $57.40
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.60
- P/E Growth: -5.19
Sales & Book Value:- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $6.82 per share
- Price / Book: 7.05
Profitability:- EBITDA: ($131,290,000.00)
- Return on Equity: -62.82%
- Return on Assets: -57.32%
Debt:- Current Ratio: 5.52%
- Quick Ratio: 5.52%
Misc:- Average Volume: 634,958 shs.
- Beta: 2.67
- Short Ratio: 10.97
Frequently Asked Questions for Esperion Therapeutics (NASDAQ:ESPR)
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics, Inc. (NASDAQ:ESPR) announced its quarterly earnings data on Tuesday, August, 8th. The company reported ($1.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.67) by $0.25. During the same period in the prior year, the business earned ($0.62) earnings per share. View Esperion Therapeutics' Earnings History.
When will Esperion Therapeutics make its next earnings announcement?
Where is Esperion Therapeutics' stock going? Where will Esperion Therapeutics' stock price be in 2017?
12 brokers have issued 12 month price targets for Esperion Therapeutics' shares. Their predictions range from $29.00 to $85.00. On average, they anticipate Esperion Therapeutics' share price to reach $59.09 in the next year. View Analyst Ratings for Esperion Therapeutics.
What are analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. According to Zacks Investment Research, "Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan. " (8/23/2017)
- 2. Needham & Company LLC analysts commented, "The FDA has agreed that the Phase III CLEAR LDL program of bempedoic acid is sufficient to support approval. This resolves a long standing issue for ESPR shares regarding the ability to get their drug approved without a completed CVOT. This regulatory confirmation comes on the heals of the positive FOURIER outcomes data for Repatha and the genetic validation of the target for bempedoic acid which was presented yesterday at the American College for Cardiology (ACC). As a result of this trifecta of positive news we are increasing our price target on ESPR to $58 from $25. We once again model US approval based on CLEAR LDL in 2020." (3/20/2017)
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Spectrum Pharmaceuticals (SPPI), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Genus plc (GNS), Medpace Holdings (MEDP), Immunomedics (IMMU), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Genomic Health (GHDX), Arena Pharmaceuticals (ARNA), Momenta Pharmaceuticals (MNTA), Cellectis S.A. (CLLS), Intellia Therapeutics (NTLA), Editas Medicine (EDIT), Albany Molecular Research (AMRI), Enanta Pharmaceuticals (ENTA), Heron Therapeutics (HRTX), BeyondSpring (BYSI) and Crispr Theraptc (CRSP).
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Timothy M. Mayleben, President, Chief Executive Officer, Director
- Narendra D. Lalwani Ph.D., FAHA, DABT, Chief Operating Officer, Executive Vice President - Research & Development
- Mary P. McGowan M.D., Chief Medical Officer
- Nicole Vitullo MBA, Independent Lead Director
- Roger S. Newton Ph.D., FAHA, FACN, Director
- Scott N. Braunstein M.D., Independent Director
- Dov A. Goldstein M.D., Independent Director
- Antonio M. Gotto Jr., M.D., Ph.D., Independent Director
Who owns Esperion Therapeutics stock?
Esperion Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include
MEDITOR GROUP LTD
(8.20%). Company insiders that own Esperion Therapeutics stock include Dov A Md Goldstein, Gilbert S Omenn, Mark E Mcgovern, Narendra D Lalwani and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.
How do I buy Esperion Therapeutics stock?
Shares of Esperion Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of Esperion Therapeutics stock can currently be purchased for approximately $48.08.
MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Esperion Therapeutics (NASDAQ:ESPR) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 4 Hold Ratings, 8 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.67) |
| Consensus Price Target: | $59.09 (22.90% upside) |
Consensus Price Target History for Esperion Therapeutics (NASDAQ:ESPR)
Analysts' Ratings History for Esperion Therapeutics (NASDAQ:ESPR)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 10/4/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $70.00 | Medium |  |
| 10/4/2017 | Northland Securities | Reiterated Rating | Buy | $72.00 | Medium | |
| 9/7/2017 | Cowen and Company | Initiated Coverage | Outperform | $64.00 | Low | |
| 8/21/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $85.00 | Low | |
| 8/11/2017 | Bank of America Corporation | Reiterated Rating | Neutral -> Neutral | $60.00 | Medium | |
| 8/9/2017 | Deutsche Bank AG | Set Price Target | Buy | $48.00 -> $64.00 | High | |
| 8/8/2017 | Needham & Company LLC | Boost Price Target | Buy -> Positive | $58.00 -> $72.00 | High | |
| 6/22/2017 | Citigroup Inc. | Reiterated Rating | Buy | | High | |
| 3/20/2017 | J P Morgan Chase & Co | Reiterated Rating | Hold | $22.00 -> $50.00 | Medium | |
| 3/20/2017 | Royal Bank Of Canada | Reiterated Rating | Hold | $45.00 | High | |
| 3/20/2017 | Credit Suisse Group | Upgrade | Underperform -> Neutral | $29.00 | High | |
| 11/6/2016 | JMP Securities | Reiterated Rating | Buy | | N/A | |
| 10/15/2016 | Chardan Capital | Reiterated Rating | Neutral | $12.50 | N/A | |
| 8/31/2016 | Barclays PLC | Set Price Target | Hold | $13.00 | N/A | |
| 7/5/2016 | WallachBeth Capital | Downgrade | Buy -> Hold | $35.00 | N/A | |
| 6/29/2016 | Lake Street Capital | Lower Price Target | Buy | $80.00 -> $27.00 | N/A | |
(Data available from 10/18/2015 forward)
Earnings History for Esperion Therapeutics (NASDAQ:ESPR)Earnings History by Quarter for Esperion Therapeutics (NASDAQ ESPR)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($1.79) | | | | | N/A | |
| 8/8/2017 | Q2 2017 | ($1.67) | ($1.92) | | | View | Listen | |
| 5/1/2017 | Q1 2017 | ($1.44) | ($1.80) | | | View | N/A | |
| 2/22/2017 | 12/31/2016 | ($1.24) | ($1.29) | | | View | N/A | |
| 11/3/2016 | Q3 | ($0.82) | ($0.77) | | | View | N/A | |
| 8/4/2016 | Q2 | ($0.78) | ($0.62) | | | View | N/A | |
| 5/4/2016 | Q116 | ($0.74) | ($0.65) | | | View | N/A | |
| 2/25/2016 | Q4 | ($0.61) | ($0.58) | | | View | N/A | |
| 11/5/2015 | Q3 | ($0.60) | ($0.57) | | | View | N/A | |
| 8/6/2015 | Q215 | ($0.58) | ($0.55) | | | View | N/A | |
| 5/7/2015 | Q115 | ($0.54) | ($0.56) | | | View | N/A | |
| 3/5/2015 | Q4 2014 | ($0.54) | ($0.49) | | | View | N/A | |
| 8/12/2014 | Q214 | ($0.55) | ($0.60) | | | View | N/A | |
| 5/12/2014 | Q1 2014 | ($0.62) | ($0.51) | | | View | N/A | |
| 3/5/2014 | | ($0.50) | ($0.63) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Esperion Therapeutics (NASDAQ:ESPR)| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q2 2017 | 1 | ($1.38) | ($1.38) | ($1.38) |
| Q3 2017 | 1 | ($1.78) | ($1.78) | ($1.78) |
| Q4 2017 | 1 | ($1.95) | ($1.95) | ($1.95) |
(Data provided by Zacks Investment Research)
Dividend History for Esperion Therapeutics (NASDAQ:ESPR)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Esperion Therapeutics (NASDAQ:ESPR)Insider Ownership Percentage: 32.50%
Institutional Ownership Percentage: 83.30%
Insider Trades by Quarter for Esperion Therapeutics (NASDAQ:ESPR)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 3/22/2017 | Dov A Md Goldstein | Director | Sell | 800,000 | $41.66 | $33,328,000.00 | |
| 3/21/2017 | Gilbert S Omenn | Director | Buy | 1,000 | $42.26 | $42,260.00 | |
| 11/1/2016 | Narendra D Lalwani | COO | Buy | 5,000 | $9.93 | $49,650.00 | |
| 7/6/2016 | Mark E Mcgovern | Director | Buy | 5,000 | $10.00 | $50,000.00 | |
| 5/4/2016 | Timothy M Mayleben | CEO | Buy | 7,000 | $14.85 | $103,950.00 | |
| 3/1/2016 | Gilbert S Omenn | Director | Buy | 5,000 | $15.28 | $76,400.00 | |
| 1/27/2016 | Timothy M Mayleben | CEO | Buy | 3,600 | $15.88 | $57,168.00 | |
| 1/15/2016 | Timothy M Mayleben | CEO | Buy | 7,200 | $14.08 | $101,376.00 | |
| 4/24/2015 | Dov A Md Goldstein | Director | Sell | 217,469 | $108.22 | $23,534,495.18 | |
| 11/18/2014 | Patrick G Enright | Director | Sell | 487,130 | $32.78 | $15,968,121.40 | |
| 10/21/2014 | Parters Vii L P Domain | Major Shareholder | Buy | 500,000 | $20.00 | $10,000,000.00 | |
| 10/7/2014 | Longitude Capital Partners, Ll | Major Shareholder | Sell | 11,927 | $30.04 | $358,287.08 | |
| 7/1/2013 | Brian H Dovey | Major Shareholder | Buy | 285,714 | $14.00 | $3,999,996.00 | |
| 7/1/2013 | Daniel Janney | Director | Buy | 235,714 | $14.00 | $3,299,996.00 | |
| 7/1/2013 | Roger S Newton | Chairman | Buy | 42,346 | $14.00 | $592,844.00 | |
| 7/1/2013 | Timothy M Mayleben | CEO | Buy | 5,000 | $14.00 | $70,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Esperion Therapeutics (NASDAQ:ESPR)
Latest Headlines for Esperion Therapeutics (NASDAQ:ESPR)
| Source: |
|
| Date | Headline |
|---|
 | Esperion to Host Analyst and Investor Day Event on October 17
finance.yahoo.com - October 10 at 4:09 PM |
 | Comparing Global Blood Therapeutics (GBT) and Esperion Therapeutics (ESPR)
www.americanbankingnews.com - October 4 at 2:10 AM |
 | VICL Soars After-hours, DMTX Deems RARE Bid Superior, MDXG On Watch - Nasdaq
www.nasdaq.com - October 3 at 8:03 AM |
 | Esperion Therapeutics (ESPR) Completes Enrollment in Phase 3 ... - StreetInsider.com
www.streetinsider.com - October 3 at 12:57 AM |
| Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid
finance.yahoo.com - October 2 at 7:55 PM |
| Esperion Therapeutics (ESPR) and Its Peers Head to Head Review
www.americanbankingnews.com - September 30 at 10:20 PM |
| Esperion Therapeutics, Inc. (ESPR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 24 at 4:40 PM |
 | Your Daily Pharma Scoop: VanEck Vectors Biotech ETF, Esperion's Growth Potential, Pfizer's EU Approval
seekingalpha.com - September 22 at 5:30 PM |
| Esperion Therapeutics Remains Undervalued - Seeking Alpha - Seeking Alpha
seekingalpha.com - September 22 at 8:23 AM |
| Reviewing Esperion Therapeutics (ESPR) & Its Competitors
www.americanbankingnews.com - September 17 at 12:32 AM |
| Brokerages Expect Esperion Therapeutics, Inc. (ESPR) to Post -$1.78 Earnings Per Share
www.americanbankingnews.com - September 14 at 4:14 PM |
| Head-To-Head Survey: Esperion Therapeutics (ESPR) vs. Its Competitors
www.americanbankingnews.com - September 14 at 8:20 AM |
| Cowen and Company Initiates Coverage on Esperion Therapeutics, Inc. (ESPR)
www.americanbankingnews.com - September 10 at 9:54 AM |
| Head to Head Contrast: ICON PLC (ICLR) & Esperion Therapeutics (ESPR)
www.americanbankingnews.com - September 2 at 6:08 AM |
| Esperion Therapeutics, Inc. (ESPR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - August 30 at 4:44 PM |
| Esperion Therapeutics, Inc. (ESPR) Now Covered by Northland Securities
www.americanbankingnews.com - August 29 at 10:16 AM |
| Cramer Remix: Here's how North Korea's missile could impact the stock market
finance.yahoo.com - August 29 at 4:15 AM |
| Esperion Therapeutics, Inc. (ESPR) to Post Q3 2017 Earnings of ($1.78) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - August 23 at 8:22 AM |
| Esperion Therapeutics, Inc. (ESPR) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - August 21 at 11:10 AM |
| Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives "Neutral" Rating from Bank of America Corporation
www.americanbankingnews.com - August 13 at 1:38 PM |
| Esperion Announces Inducement Grants Under NASDAQ Listing ... - Nasdaq
www.nasdaq.com - August 12 at 4:55 AM |
| Jefferies Group Weighs in on Esperion Therapeutics, Inc.'s Q3 2017 Earnings (NASDAQ:ESPR)
www.americanbankingnews.com - August 11 at 9:34 AM |
| Esperion Therapeutics (ESPR) Prices 3.1M Share Common Offering at $49/Sh
www.streetinsider.com - August 10 at 7:43 PM |
| Esperion Prices Public Offering of Common Stock
finance.yahoo.com - August 9 at 11:39 PM |
 | Benzinga's Top Upgrades, Downgrades For August 9, 2017 - Benzinga
www.benzinga.com - August 9 at 6:37 PM |
| Positive Triplet Data Should Accelerate Esperion Deal-Making Chatter - Seeking Alpha
seekingalpha.com - August 9 at 6:37 PM |
| Edited Transcript of ESPR earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 9 at 4:10 AM |
| Esperion Therapeutics' (ESPR) CEO Tim Mayleben on Q2 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - August 8 at 11:10 PM |
| Esperion Therapeutics, Inc. (ESPR) Expected to Announce Earnings of -$1.67 Per Share
www.americanbankingnews.com - August 8 at 6:24 PM |
| Esperion Therapeutics (ESPR) Says Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin Met ... - StreetInsider.com
www.streetinsider.com - August 8 at 6:09 PM |
| Investor Network: Esperion Therapeutics, Inc. to Host Earnings Call
finance.yahoo.com - August 8 at 6:09 PM |
| Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus Atorvastatin
finance.yahoo.com - August 8 at 6:09 PM |
| Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 8 at 6:09 PM |
| Here's What's Pushing Up Esperion Therapeutics Inc. Today
finance.yahoo.com - August 8 at 6:09 PM |
| Esperion Announces Proposed Public Offering of Common Stock
finance.yahoo.com - August 8 at 6:08 PM |
| Esperion Therapeutics reports 2Q loss
finance.yahoo.com - August 8 at 6:08 PM |
| Esperion Therapeutics, Inc. (ESPR) Upgraded by Jefferies Group LLC to Buy
www.americanbankingnews.com - August 8 at 5:42 PM |
| Esperion Therapeutics, Inc. (ESPR) Releases Quarterly Earnings Results, Misses Estimates By $0.30 EPS
www.americanbankingnews.com - August 8 at 3:48 PM |
| Needham & Company LLC Increases Esperion Therapeutics, Inc. (NASDAQ:ESPR) Price Target to $72.00
www.americanbankingnews.com - August 8 at 1:20 PM |
| Should You Buy Esperion Therapeutics (ESPR) Ahead of Earnings?
finance.yahoo.com - August 7 at 6:41 PM |
| Esperion Therapeutics Inc (NASDAQ:ESPR) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 5 at 4:40 PM |
| Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results
finance.yahoo.com - August 2 at 7:20 PM |
| Juno Therapeutics (JUNO) Q2 Earnings: Surprise in Store?
www.nasdaq.com - July 27 at 11:59 PM |
| Esperion Therapeutics (ESPR) Reports Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
www.streetinsider.com - July 27 at 11:59 PM |
 | The CEO Behind Lipitor Is Working on a Promising New Cholesterol Drug - Motley Fool
www.fool.com - July 26 at 6:59 PM |
| Esperion Therapeutics (ESPR) Reports Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor - StreetInsider.com
www.streetinsider.com - July 26 at 6:59 PM |
| Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor
finance.yahoo.com - July 26 at 6:59 PM |
| 3 Small Biotech Stocks Being Run by Proven Winners
finance.yahoo.com - July 17 at 10:56 AM |
| Esperion Therapeutics, Inc. (ESPR) to Post Q2 2017 Earnings of ($1.38) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - July 13 at 10:02 AM |
| Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 11 at 5:34 PM |
Esperion Therapeutics (ESPR) Chart for Wednesday, October, 18, 2017
